5 May 2021 - - US-based biopharmaceutical company Vividion Therapeutics, Inc has appointed Christine Siu, a life sciences industry leader with more than 20 years of experience in corporate development, strategy and financial roles, to the company's board of directors, the company said.

Siu brings a strong track record of creating value and integrating financing strategy with corporate development to the Vividion board of directors.

Siu is the chief operating officer in-residence at BridgeBio Pharma, Inc, and former chief financial officer at Eidos Therapeutics, Inc., a BridgeBio subsidiary, where she transformed Eidos from a preclinical biotech start-up company to a late-stage clinical public company.

Prior to that, she was the chief business officer at The Bluefield Project to Cure Frontotemporal Dementia, where she built a therapeutic pipeline and executed seven collaborations with the pharmaceutical industry.

Earlier, she was senior director, corporate development at Global Blood Therapeutics, Inc., and before that, a venture principal at Third Rock Ventures, where she was part of the GBT launch team and first employee at GBT.

Previously, Siu invested in life science companies in venture capital and private equity and held roles of increasing responsibility at Warburg Pincus LLC and Thomas, McNerney and Partners, LLC and began her career in healthcare banking at Bear, Stearns and Co. Inc.

Siu holds an MBA from Harvard Business School and a B.S. with distinction in cellular molecular biology and economics from the University of Michigan.

Vividion Therapeutics is a biopharmaceutical company utilizing novel discovery technologies to unlock traditionally undruggable targets with precision therapeutics for devastating cancers and immune disorders.